# Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Canonical URL: https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-fda-acceptance-of-nda-for-lorundrostat-for-treatment-of-adults-with-hypertension-and-topline-explore-osa-trial-results
Ticker: MLYS
Company: Mineralys Therapeutics
Source: Mineralys Therapeutics
Published: 2026-03-09 20:30 EST
Original Source URL: https://ir.mineralystx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-27 20:01 EST — [Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635--a1d96146) — Source: Mineralys Therapeutics
- 2026-06-14 14:00 EST — [Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-and-heart-fai-35eaa6f1) — Source: Mineralys Therapeutics
- 2026-06-08 20:05 EST — [Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-he-6027ff68) — Source: Mineralys Therapeutics
- 2026-06-08 11:00 EST — [Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-present-late-breaking-data-on-lorundrostat-at-the-endo-03fb3c48) — Source: Mineralys Therapeutics
- 2026-06-03 10:05 EST — [Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-pricing-of-150-million-underwritten-offering-of-common-stock) — Source: Mineralys Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)